Coronary Artery DiseaseNCT03871907
Effect of Digital Technologies on Risk Factor Modification
A study testing Digital technology in people with Coronary Artery Disease, run by Tomsk National Research Medical Center of the Russian Academy of Sciences at 1 site in Russia.
Trial summary
DigTech investigates the effect of a text message-based intervention to encourage lifestyle change on objective measures of cardiovascular risk in individuals with coronary heart disease (CHD) after percutaneous coronary intervention (PCI). DigTech will recruit 700 participants from 18-75 years old with CHD after PCI. Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- Digital technology
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 700 participants
- Where
- 1 siteRussia
- Study dates
- 11 Mar 2019to 1 Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients with coronary artery disease at the age of 18 to 75 years who are planning PCI for hemodynamically significant coronary artery stenosis.
Who cannot join
- Severe comorbidities (malignant tumors, severe lung diseases, marked cognitive impairment).
- Severe CHF (EF LV <35% or functional class of heart failure III-IV NYHA).
- Severe valvular heart disease or Prosthetic heart valves.
- Severe diseases of the musculoskeletal system.
- The patient's reluctance to participate in the study.
Trial locations and contacts
1 site in 1 country.
Russia1 site
Tyumen Cardiology Research Center, Tomsk National Research Medical Center, Russian Academy of Science
Tyumen, 625026
About this study
Official title: Effect of Digital Technologies on Risk Factor Modification in Patients After Percutaneous
DigTech investigates the effect of a text message-based intervention to encourage lifestyle change on objective measures of cardiovascular risk in individuals with coronary heart disease (CHD) after percutaneous coronary intervention (PCI).
DigTech will recruit 700 participants from 18-75 years old with CHD after PCI. Half of the participants will be randomised into a 24 week intervention trial, which includes sending 4 personalized short messages about risk factors modification 4 times per week and the other half will be controls.
Read more
Participants will complete 3 main study visits:
- Visit 1: Baseline visit conducted at the beginning of the study
- Visit 2: Randomization
- Visit 3: End of study (24 weeks). Each visit will repeat the same set of cardiovascular measures including information about previous treatment, blood pressure, ECG, echocardiography, stress tests, blood sampling, International Physical Activity Questionnaires (IPAQ) and other measures.
Read the detailed description
DESIGN: DigTech is a parallel-group, single-blind, randomized clinical trial investigating the changes in cardiovascular risk factors (low-density lipoprotein cholesterol [LDL-C] level, blood pressure, body mass index [BMI]) according to personalized intervention, based on individual short messages in CHD patients after PCI.
BACKGROUND AND AIMS:
Cardiovascular disease prevention, including lifestyle modification, is important but underutilized. Mobile health strategies could address this gap but lack evidence of therapeutic benefit.
This trial aims at the examination of the effect of a lifestyle-focused personalized support program delivered by mobile phone text message on cardiovascular risk factors.
PARTICIPANTS: 700 participants aged 18-75 with CHD after PCI.
RECRUITMENT: Tyumen Cardiology Research Center, branch of the Tomsk NRMC
CONFIDENTIALITY: All information and documents collected will be stored securely and kept in strict confidence in compliance with regulatory acts.
Study samples, investigation results and incidental findings. The use of the participants' study samples and investigations are clearly defined in the participant information leaflet and will be explained during the informed consent process.
CONSIDERATION OF NULL HYPOTHESES: A null hypotheses that personalized lifestyle intervention based on received 4 text messages per week for 6 months in addition to usual care in CHD patients after PCI does not reduce LDL-C levels, blood pressure and BMI" was not selected.
SAMPLE SIZE SELECTION: Prior study shows that a sample size of 634, increasing to 704 to allow for a10% loss to follow-up, would have 90% power (2-tailed and at a 5% significance level) to detect a difference of 10 mg/dL in LDL-C level.
INTERVENTION: The text message will be based on the prevention program involved delivery of regular personalized text messages (some messages personally addressed through a "mail-merge"-type function with the participant's preferred name) providing advice, motivation, and information that is aimed to improve diet, increase physical activity, and encourage smoking cessation (if relevant). Content for each participant will be selected using a re-specified algorithm dependent on key baseline characteristics. Participants will receive 4 messages per week for 24 weeks. Each message will be sent on 4 of 5 randomly selected days and arrived at random times of the day during working hours. The content of messages will be based on national guidelines on cardiovascular disease prevention.
STUDY PROCEDURES AND DATA COLLECTION
SCREENING VISITS: Screening Visit Procedures (Visit 0). Evaluation of inclusion and exclusion criteria. Patients will provide written informed consent on this visit.
MAIN STUDY VISITS COMPLETION OF STUDY VISITS 1-3
There are three main visits planned for each participant:
Visit 1: conducted at the beginning of trial (baseline).
- Questionnaire. It will collect detailed information about physical activities (International Physical Activity Questionnaires short form) and also lifestyle information such as daily routines and use of alcohol and tobacco, information about previous treatment.
- Physical Measures. Investigators will measure blood pressure, height, weight, BMI, heart rate.
- Cardiovascular Measures:
- Electrocardiogram (ECG).
- Echocardiogram
- Six Minute Walk Test.
- Coronary angiography
- Blood Sampling including blood lipid spectrum (total cholesterol, triglycerides, cholesterol high-density lipoproteins and cholesterol low-density lipoproteins). Fasting blood samples will be analyzed by local laboratories.
Visit 2: Randomization. Randomization will be performed after PCI, prior to discharge from the hospital.
Randomization will occur via a computerized randomization program that will access through a secure web interface. The random allocation sequence will be in a uniform 1:1 and will be concealed from study personnel. Study staff will enroll patients by entering data into the secure web interface. The computerized randomization program interfaced with the message-sending program to trigger the sending of messages to patients randomized to the intervention. To maintain blinding of personnel study, patients will be informed of their allocation in a text message sent after hospital discharge. Prior to their follow-up appointment patients also will receive a text message to ask them not to reveal their allocation status to study personnel or clinicians in follow-up visits. Intervention participants will receive, in addition to usual care, the 6-months prevention program of approximately 96 messages. Control participants will receive usual care, which generally included community follow-up with the majority referred to inpatient cardiac rehabilitation, as determined by their usual physicians.
Visit 3: conducted after 24 weeks (at the end of the trial, Follow-up visit).
ANALYSIS: Patient demographic characteristics and other baseline information will be summarised by treatment group. Numbers (with percentages) for binary and categorical variables and mean (standard deviation), or median (interquartile or full range) for continuous variables will be presented. Normality of variables will be assessed by visual assessment of the normality curves and the Kolmogorov-Smirnov test. The analysis of the primary outcome will be assessed using analysis of covariance (ANCOVA) adjusting for baseline values and minimisation factors used in the randomisation process. Results will be presented as adjusted mean difference in change in ambulatory blood pressure between randomised groups at 4 months with 95% confidence intervals (CI) and associated two-sided p value. The above method was also used for continuous secondary outcomes. With respect to management of combined risk factors, the proportion of patients achieving control of risk factors was analyzed in terms of relative risk at month 6 and compared between groups using a log-binomial regression. If the model assumptions are not met and evidence of departure from Normality is observed, transformations of the data will be employed or non-parametric tests will be carried out. Statistical analysis will be carried out using SPSS statistical software.
- Conditions
- Coronary Artery Disease
- Being tested
- Digital technology
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital technologyBehavioural
Lifestyle-Focused Text Messaging
| Study group | Role | What they receive |
|---|---|---|
| Digital technology | Active comparator | standard cardiac rehabilitation program + 4 personalized short messages about risk factors modification 4 times per week Receives: Behavioral: Digital technology |
| Control | No intervention | standard cardiac rehabilitation program |
What is being measured
The primary outcome is the main question the study is designed to answer.
Low-density lipoprotein cholesterol level at 6 months
The primary end point was low-density lipoprotein cholesterol level at 6 months
Measured: 6 months
Secondary outcomes (2)
Systolic blood pressure
Systolic blood pressure will be lower in the intervention group compared with the control group
Measured: 6 months
Body mass index (BMI)
Body mass index (weight and height will be combined to report BMI in kg/m^2) will be lower in the intervention group compared with the control group
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2019
- Study start11 Mar 2019
- Primary completion31 Dec 2020
- Study completion1 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 700 participants (actual)
Sponsor and investigators
- Lead sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Sergey V Popov, Principal investigator, Tomsk National Research Medical Center of the Russian Academy of Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03871907
- Sponsor's protocol ID
- TCRC-146/2
- Status last verified
- Jun 2026
- First submitted
- 6 Mar 2019
- Last updated
- 24 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Digital Technologies on Risk Factor Modification in Patients After Percutaneous
- ClinicalTrials.gov ID
- NCT03871907
- Acronym / sponsor ID
- TCRC-146/2
- Conditions
- Coronary Artery Disease
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 700 participants (actual)
- Lead sponsor
- Tomsk National Research Medical Center of the Russian Academy of SciencesUniversity, hospital or other
- Study start
- 11 Mar 2019 (actual)
- Primary completion
- 31 Dec 2020 (actual)
- Study completion
- 1 Dec 2021 (actual)
- First posted
- 12 Mar 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
DigTech investigates the effect of a text message-based intervention to encourage lifestyle change on objective measures of cardiovascular risk in individuals with coronary heart disease (CHD) after percutaneous coronary intervention (PCI).
DigTech will recruit 700 participants from 18-75 years old with CHD after PCI. Half of the participants will be randomised into a 24 week intervention trial, which includes sending 4 personalized short messages about risk factors modification 4 times per week and the other half will be controls.
Participants will complete 3 main study visits:
- Visit 1: Baseline visit conducted at the beginning of the study
- Visit 2: Randomization
- Visit 3: End of study (24 weeks). Each visit will repeat the same set of cardiovascular measures including information about previous treatment, blood pressure, ECG, echocardiography, stress tests, blood sampling, International Physical Activity Questionnaires (IPAQ) and other measures.
Detailed description
DESIGN: DigTech is a parallel-group, single-blind, randomized clinical trial investigating the changes in cardiovascular risk factors (low-density lipoprotein cholesterol [LDL-C] level, blood pressure, body mass index [BMI]) according to personalized intervention, based on individual short messages in CHD patients after PCI.
BACKGROUND AND AIMS:
Cardiovascular disease prevention, including lifestyle modification, is important but underutilized. Mobile health strategies could address this gap but lack evidence of therapeutic benefit.
This trial aims at the examination of the effect of a lifestyle-focused personalized support program delivered by mobile phone text message on cardiovascular risk factors.
PARTICIPANTS: 700 participants aged 18-75 with CHD after PCI.
RECRUITMENT: Tyumen Cardiology Research Center, branch of the Tomsk NRMC
CONFIDENTIALITY: All information and documents collected will be stored securely and kept in strict confidence in compliance with regulatory acts.
Study samples, investigation results and incidental findings. The use of the participants' study samples and investigations are clearly defined in the participant information leaflet and will be explained during the informed consent process.
CONSIDERATION OF NULL HYPOTHESES: A null hypotheses that personalized lifestyle intervention based on received 4 text messages per week for 6 months in addition to usual care in CHD patients after PCI does not reduce LDL-C levels, blood pressure and BMI" was not selected.
SAMPLE SIZE SELECTION: Prior study shows that a sample size of 634, increasing to 704 to allow for a10% loss to follow-up, would have 90% power (2-tailed and at a 5% significance level) to detect a difference of 10 mg/dL in LDL-C level.
INTERVENTION: The text message will be based on the prevention program involved delivery of regular personalized text messages (some messages personally addressed through a "mail-merge"-type function with the participant's preferred name) providing advice, motivation, and information that is aimed to improve diet, increase physical activity, and encourage smoking cessation (if relevant). Content for each participant will be selected using a re-specified algorithm dependent on key baseline characteristics. Participants will receive 4 messages per week for 24 weeks. Each message will be sent on 4 of 5 randomly selected days and arrived at random times of the day during working hours. The content of messages will be based on national guidelines on cardiovascular disease prevention.
STUDY PROCEDURES AND DATA COLLECTION
SCREENING VISITS: Screening Visit Procedures (Visit 0). Evaluation of inclusion and exclusion criteria. Patients will provide written informed consent on this visit.
MAIN STUDY VISITS COMPLETION OF STUDY VISITS 1-3
There are three main visits planned for each participant:
Visit 1: conducted at the beginning of trial (baseline).
- Questionnaire. It will collect detailed information about physical activities (International Physical Activity Questionnaires short form) and also lifestyle information such as daily routines and use of alcohol and tobacco, information about previous treatment.
- Physical Measures. Investigators will measure blood pressure, height, weight, BMI, heart rate.
- Cardiovascular Measures:
- Electrocardiogram (ECG).
- Echocardiogram
- Six Minute Walk Test.
- Coronary angiography
- Blood Sampling including blood lipid spectrum (total cholesterol, triglycerides, cholesterol high-density lipoproteins and cholesterol low-density lipoproteins). Fasting blood samples will be analyzed by local laboratories.
Visit 2: Randomization. Randomization will be performed after PCI, prior to discharge from the hospital.
Randomization will occur via a computerized randomization program that will access through a secure web interface. The random allocation sequence will be in a uniform 1:1 and will be concealed from study personnel. Study staff will enroll patients by entering data into the secure web interface. The computerized randomization program interfaced with the message-sending program to trigger the sending of messages to patients randomized to the intervention. To maintain blinding of personnel study, patients will be informed of their allocation in a text message sent after hospital discharge. Prior to their follow-up appointment patients also will receive a text message to ask them not to reveal their allocation status to study personnel or clinicians in follow-up visits. Intervention participants will receive, in addition to usual care, the 6-months prevention program of approximately 96 messages. Control participants will receive usual care, which generally included community follow-up with the majority referred to inpatient cardiac rehabilitation, as determined by their usual physicians.
Visit 3: conducted after 24 weeks (at the end of the trial, Follow-up visit).
ANALYSIS: Patient demographic characteristics and other baseline information will be summarised by treatment group. Numbers (with percentages) for binary and categorical variables and mean (standard deviation), or median (interquartile or full range) for continuous variables will be presented. Normality of variables will be assessed by visual assessment of the normality curves and the Kolmogorov-Smirnov test. The analysis of the primary outcome will be assessed using analysis of covariance (ANCOVA) adjusting for baseline values and minimisation factors used in the randomisation process. Results will be presented as adjusted mean difference in change in ambulatory blood pressure between randomised groups at 4 months with 95% confidence intervals (CI) and associated two-sided p value. The above method was also used for continuous secondary outcomes. With respect to management of combined risk factors, the proportion of patients achieving control of risk factors was analyzed in terms of relative risk at month 6 and compared between groups using a log-binomial regression. If the model assumptions are not met and evidence of departure from Normality is observed, transformations of the data will be employed or non-parametric tests will be carried out. Statistical analysis will be carried out using SPSS statistical software.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Digital technology | Active comparator | Behavioral: Digital technologystandard cardiac rehabilitation program + 4 personalized short messages about risk factors modification 4 times per week |
| Control | No intervention | –standard cardiac rehabilitation program |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Patients with coronary artery disease at the age of 18 to 75 years who are planning PCI for hemodynamically significant coronary artery stenosis.
Key exclusion criteria (5 listed)
- Severe comorbidities (malignant tumors, severe lung diseases, marked cognitive impairment).
- Severe CHF (EF LV <35% or functional class of heart failure III-IV NYHA).
- Severe valvular heart disease or Prosthetic heart valves.
- Severe diseases of the musculoskeletal system.
- The patient's reluctance to participate in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Digital technologyLifestyle-Focused Text Messaging | Behavioural | Digital technology |
Primary outcome
Low-density lipoprotein cholesterol level at 6 months
Time frame: 6 months
The primary end point was low-density lipoprotein cholesterol level at 6 months
2 secondary outcomes
Systolic blood pressure
Time frame: 6 months
Body mass index (BMI)
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Jun 2026.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Disease
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Active, not recruitingPhase 4
Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD
Coronary Artery Disease
RecruitingPhase 4
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome
ACS (Acute Coronary Syndrome), SGLT2 Inhibitors
Not yet recruiting
Effect of Propionic Acid Supplementation on Endothelial Function
Cardiovascular Diseases, Endothelial Dysfunction
Recruiting
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With Stable Angina or ACS - A Traditional Feasibility Study
Coronary Arterial Disease (CAD), Plaque
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Sergey V Popov principal investigator
Tomsk National Research Medical Center of the Russian Academy of Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Digital technology in people with Coronary Artery Disease, run by Tomsk National Research Medical Center of the Russian Academy of Sciences at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Low-density lipoprotein cholesterol level at 6 months (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jun 2026.